Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Realigns into Three Units

NEW YORK (GenomeWeb News) – Sigma-Aldrich said on Monday that it has realigned the firm into three market-focused businesses intended to better serve its customers and drive sales growth.

The St. Louis-based chemicals and research tools firm said that its new Applied Markets Business Unit will serve its customers in the diagnostics, testing, and industrial markets. Frank Wicks, who currently serves as president of the research business will be president of this division.

The new Research Markets Business Unit will focus on selling research products to scientists in the life science, academic, government, and hospital markets around the world. It will be led by Eric Green, who currently serves as VP and managing director of the International region.

Its SAFC business will be renamed the SAFC Commercial Markets Business Unit and will continue to focus on customers in the life science and electronic markets. Gilles Cottier will continue to lead this business.

Sigma-Aldrich previously reported financial results for its Research Chemicals unit, which consisted of Research Essentials, Research Specialties, and Research Biotech, and for SAFC.

It said that it will provide more information about the structure, sales, and growth prospects of each of the three new business units when it reports its Fiscal Year 2012 financial results early in 2013.

Filed under

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.